Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)

NCT04300244 is registered in ClinicalTrials.gov with Åslaug Helland as lead sponsor.

NCT NCT04300244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04300244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)
Lead sponsor
Åslaug Helland
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 4, 2020
Completion date
March 15, 2027
Enrollment
118 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer of lung, cancer, lung, mesothelioma, mesothelioma; lung, mesothelioma; pleura, mesotheliomas pleural